Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma Review uri icon

Overview

MeSH Major

  • Acetylmuramyl-Alanyl-Isoglutamine
  • Bone Neoplasms
  • Osteosarcoma
  • Phosphatidylethanolamines

abstract

  • Osteosarcoma is an ultraorphan disease. There are approximately 1000 new patients diagnosed with osteosarcoma each year in the USA and Europe. Current treatment for osteosarcoma utilizes multiagent chemotherapy and surgical resection of all clinically detectable disease. Current treatments for osteosarcoma achieve 60-70% event-free survival (EFS) for patients with localized disease and approximately 20% EFS for patients who present with metastasis. These results have been stable for two decades. The addition of muramyl tripeptide (mifamurtide) to chemotherapy resulted in a trend towards improved EFS and a one-third reduction in the risk of death from osteosarcoma. Mifamurtide has been approved in Europe for the treatment of newly diagnosed osteosarcoma in combination with chemotherapy.

publication date

  • August 2009

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1586/ERA.09.69

PubMed ID

  • 19671023

Additional Document Info

start page

  • 1035

end page

  • 49

volume

  • 9

number

  • 8